^
    Back
    Association details:
    Biomarker:NDUFA4L2 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Ther Adv Med Oncol
    Title:

    NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer

    Published date:
    06/30/2021
    Excerpt:
    High expression level of NDUFA4L2 was associated with shorter relapse-free intervals in trastuzumab-treated HER2-positive breast cancer patients.
    DOI:
    10.1177/17588359211027836